Analyst Targets Span 12.90 to 46 Euros as Gerresheimer's Accounting Crisis Fuels Uncertainty

Gerresheimer's accounting scandal triggers extreme analyst spread (250%+), overbought stock, auditor probe, and legal actions; shares down 45% YoY.

The gulf between the most bullish and most bearish analyst calls on Gerresheimer has rarely been wider. JPMorgan sees the stock at €46, UBS at €12.90 — a spread of more than 250 percent that screams one thing: the market is flying blind. With audited financials still unpublished, the German packaging and drug-delivery specialist is trading on hope, guesswork, and a growing pile of legal and regulatory headaches.

At Wednesday's close, the shares stood at €26.08, roughly 5.5 percent below the prior week. The stock has clawed back more than 60 percent from its February nadir of €14.90, but the 12-month chart tells a different story: a 45 percent decline. The recent rally has pushed the relative strength index to 82.3, a textbook overbought reading, even as the 200-day moving average at €26.31 sits just above the current price. The 52-week high of €50.25 remains 48 percent out of reach, and annualised 30-day volatility of nearly 48 percent underscores how violently the name swings on any fresh news.

The bill-and-hold bombshell

At the heart of the crisis is a systematic accounting failure. Gerresheimer recorded revenue from so-called bill-and-hold transactions — billing customers for goods not yet delivered — in breach of IFRS rules. An independent law firm confirmed the irregularities, which inflated sales by €35 million and adjusted EBITDA by €24 million. Further question marks hang over €65.5 million in lease liabilities and €29.4 million in capitalised development costs.

The auditor switch added fuel to the fire. KPMG took over from Deloitte in 2024 and issued an unqualified opinion on the 2024 annual accounts. Germany's audit oversight body, APAS, has now launched proceedings against KPMG for allegedly signing off on financial statements that contained systematic revenue recognition errors.

Creditors buy time, management acts

In April, holders of €870 million in Schuldschein loans voted 96 percent in favour of a deadline extension, pushing the requirement for audited accounts back to September 2026. Key leverage covenants have been waived in the interim. The company itself has targeted June 2026 for the 2025 audit — but that target assumes the ongoing BaFin probe and internal reviews do not cause further delays.

Operationally, Gerresheimer is moving on multiple fronts. The plant in Chicago Heights will close by September 2026, with 172 jobs cut and production relocated to Italy and India. Non-cash impairments of between €220 million and €240 million are planned for 2025, hitting the US site and the subsidiary Sensile Medical. Meanwhile, the sale of US packaging unit Centor — carried at €292 million on the books at end-2024 — is being run by Morgan Stanley, and a double-digit number of interested parties have emerged.

Legal heat on former executives

The DSW shareholder protection association has commissioned a legal opinion to assess damages claims against former CEO Dietmar Siemssen and former CFO Bernd Metzner. Supervisory board and audit committee members are also under scrutiny. DSW managing director Marc Tüngler said the more concrete the claims become, the more likely a litigation funder will step in. At issue are goodwill items worth €676 million whose valuation is being challenged.

A slim silver lining

Despite the chaos, Gerresheimer has not pulled its 2026 outlook: revenue of €2.3 billion to €2.4 billion, an adjusted EBITDA margin of 18 to 19 percent, and modestly positive free cash flow. The guidance, however, is contingent on successful credit negotiations and the outcome of the BaFin investigation.

A recent cooperation with Newel Health, announced in late May, aims to combine Gerresheimer's drug-delivery and digital-health expertise with Newel's AI-powered H-Core platform. Whether that partnership moves the needle on credibility remains doubtful while the balance sheet is still unaudited.

Short interest stands at roughly 11 percent of registrable shares. A few shorts, like Arrowstreet Capital, have trimmed positions — a signal that the rally from around €26 has not gone unnoticed. But the real test comes in June, when the audited 2025 annual report is due. If it arrives, it will be the first reliable data point since the crisis erupted, and could trigger a repricing. If it does not, all eyes turn to the September 2026 creditor deadline — and the pressure on the stock will only build.